Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Amouri, I ^a   Sellami, H ^a   Borji, N ^b   Abbes, S ^a   Sellami, A ^a   Cheikhrouhou, F ^a   Maazoun, L ^b   Khaled, S ^a   Khrouf, S ^b   Boujelben, Y ^c   Ayadi, A ^a  

^a UNIVERSITY OF SFAX   (Tunisia)

^b Regional Center of Family and Population Education   (Tunisia)

^c UNIVERSITY OF SFAX   (Tunisia)

Author keywords

Candida spp; Epidemiology; Recurrences; Risk factors; Vulvovaginal candidosis

Indexed keywords

SPERMICIDAL AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CONDOM; DIABETES CONTROL; DYSPAREUNIA; DYSURIA; EMPLOYMENT STATUS; FEMALE; FUNGUS CULTURE; GENITAL TRACT INFECTION; HEALTH SURVEY; HUMAN; INCIDENCE; INFECTION RISK; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; RISK ASSESSMENT; TUNISIA; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINAL BURNING SENSATION; VAGINAL PRURITUS;

ADOLESCENT; ADULT; CANDIDA; CANDIDIASIS, VULVOVAGINAL; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TUNISIA; YOUNG ADULT;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA;

EID: 80052803888     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01965.x     Document Type: Article

References (35)

1. Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 2000; 61: 3306-12, 17.
2. Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369: 1961-71.
3. MacNeill C, Carey JC. Recurrent vulvovaginal candidiasis. Curr Womens Health Rep 2001; 1: 31-35.
4. Patel DA, Gillespie B, Sobel JD et al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obstet Gynecol 2004; 190: 644-53.
5. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55: 1-94.
6. Holland J, Young ML, Lee O, S CAC. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect 2003; 79: 249-50.
7. Abu-Elteen KH. Increased incidence of vulvovaginal candidiasis caused by Candida glabrata in Jordan. Jpn J Infect Dis 2001; 54: 103-7.
8. Corsello S, Spinillo A, Osnengo G et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003; 110: 66-72.
9. Rylander E, Berglund AL, Krassny C, Petrini B. Vulvovaginal Candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect 2004; 80: 54-57.
10. Reed BD, Gorenflo DW, Gillespie BW, Pierson CL, Zazove P. Sexual behaviors and other risk factors for Candida vulvovaginitis. J Womens Health Gend Based Med 2000; 9: 645-55.
11. De Vos MM, Cuenca-Estrella M, Boekhout T et al. Vulvovaginal candidiasis in a Flemish patient population. Clin Microbiol Infect 2005; 11: 1005-11.
12. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985; 152: 924-35.
13. Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006; 126: 121-5.
14. Stricker T, Navratil F, Sennhauser FH. Vulvovaginitis in prepubertal girls. Arch Dis Child 2003; 88: 324-6.
15. Ehrstrom SM, Kornfeld D, Thuresson J, Rylander E. Signs of chronic stress in women with recurrent Candida vulvovaginitis. Am J Obstet Gynecol 2005; 193: 1376-81.
16. Watson C, Calabretto H. Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. Aust N Z J Obstet Gynaecol 2007; 47: 262-72.
17. de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002; 2: 1.
18. Malazy OT, Shariat M, Heshmat R et al. Vulvovaginal candidiasis and its related factors in diabetic women. Taiwan J Obstet Gynecol 2007; 46: 399-404.
19. Giraldo P, von Nowaskonski A, Gomes FA, Linhares I, Neves NA, Witkin SS. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol 2000; 95: 413-6.
20. Demirezen S, Dirlik OO, Beksac MS. The association of Candida infection with intrauterine contraceptive device. Cent Eur J Public Health 2005; 13: 32-34.
21. Chassot F, Negri MF, Svidzinski AE et al. Can intrauterine contraceptive devices be a Candida albicans reservoir? Contraception 2008; 77: 355-9.
22. Bohbot JM. Les mycoses génitales chroniques. Physiopathologie, traitement: jusqu'à où aller? Réalité en gynécologie-obstétrique 1995; 5: 29-38.
23. Karaer A, Boylu M, Avsar AF. Vaginitis in Turkish women: symptoms, epidemiologic-microbiologic association. Eur J Obstet Gynecol Reprod Biol 2005; 121: 211-5.
24. Cetin M, Ocak S, Gungoren A, Hakverdi AU. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. Scand J Infect Dis 2007; 39: 584-8.
25. McGroarty JA, Soboh F, Bruce AW, Reid G. The spermicidal compound nonoxynol-9 increases adhesion of Candida species to human epithelial cells in vitro. Infect Immun 1990; 58: 2005-7.
26. Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003; 37: 733-7.
27. Rosentul D, Joosten LAB, van der Meer JWM, Kullberg BJ, Netea MG. Polymorphism in innate immunity genes and susceptibility to recurrent vulvovaginal candidiasis. J Mycol Med 2009; 19: 191-6.
28. Consolaro MEL, Albertoni AT, Yoshida CS, Mazucheli J, Peralta RM, Svidzinski TIE. Correlation of Candida species and symptoms among patients with vulvovaginal candidiasis in Maringá, Paraná, Brazil. Rev Iberoam Micol 2004; 21: 202-5.
29. Geiger AM, Foxman B, Sobel JD. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C. glabrata and no Candida. Genitourin Med 1995; 71: 304-7.
30. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80-96.
31. Bauters TG, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002; 187: 569-74.
32. Mohanty S, Xess I, Hasan F, Kapil A, Mittal S, Tolosa JE. Prevalence & susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res 2007; 126: 216-9.
33. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155-62.
34. Mathema B, Cross E, Dun E et al. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 2001; 33: E23-27.
35. Sojakova M, Liptajova D, Borovsky M, Subik J. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia. Mycopathologia 2004; 157: 163-9.